The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | ASH: setting the scene for new standards of care
The American Society of Hematology (ASH) Annual Meeting and Exposition has become the go-to place for hematology updates for scientists, clinicians, those in the industry and other stakeholders. As described by this year’s ASH President, Kenneth Anderson, MD, of the Dana-Farber Cancer Institute, Boston, MA, the meeting is known to be a place where highly anticipated information is always presented, including novel drug approvals and clinical updates. Dr Anderson describes the major topical updates at the meeting this year, as well as the last 2 years. This year’s meeting presents 20 novel approved agents spanning different therapy types, which are setting the stage for new standards of care across a range of hematological pathologies.
